Research programme: anticancer therapeutics - Dekk-Tec/Tigris PharmaceuticalsAlternative Names: A 007 analogues - Tigris Pharmaceuticals; A-024; Sivifene analogues - Tigris Pharmaceuticals
Latest Information Update: 23 Jan 2008
At a glance
- Originator Barbara Ann Karmanos Cancer Institute; Dekk-Tec
- Developer Tigris Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 Oct 2005 Preclinical trials in Cancer in USA (Topical)